国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水

 
Guideview > FDA
  • 2024 FDA Issued CRLs
    2024 FDA Issued CRLs FDA The FDA issued Complete Response Letters (CRLs) for multiple drug applications in 2024, citing concerns about efficacy, safety, and manufacturing. Learn about the rejected drugs, reasons behind CRLs, and their impact on pharmaceutical companies.
  • Will the FDA Conduct Large-Scale Layoffs?
    Will the FDA Conduct Large-Scale Layoffs? FDA Will the FDA Conduct Large-Scale Layoffs? Check out the voting results at LinkedIn or X (Twitter) now!
  • Trump's Presidency: Impact on the U.S. Biopharma Industry
    Trump's Presidency: Impact on the U.S. Biopharma Industry FDA Explore the implications of Trump's return on U.S. biopharma: healthcare cost reforms, IRA adjustments, reshoring manufacturing, and FDA/NIH shifts. Key focus areas for Chinese pharma include supply chain resilience and navigating new cross-border data regulations.
  • Drug RA | FDA: December 2024 Training: Innovative Therapies - Gene Therapy
    Drug RA | FDA: December 2024 Training: Innovative Therapies - Gene Therapy FDA The FDA's December 2024 Clinical Investigator Training Course focused on gene therapy, covering key stages in the development of cell and gene therapies. The session also introduced new initiatives to support rare disease treatments and improve regulatory processes.
  • Identification and Classification of Mutagenic Impurities from FDA Deficiency Letters
    Identification and Classification of Mutagenic Impurities from FDA Deficiency Letters FDA Explore the identification, classification, and control of mutagenic impurities in pharmaceuticals. Learn about ICH M7 guidance, QSAR evaluation, and FDA requirements for mutagenicity risk assessment in drug submissions.
  • FDA Official Departure Wave?
    FDA Official Departure Wave? FDA Dr. Patrizia Cavazzoni, FDA's CDER Director, announces her departure next week, following several senior FDA officials. The changes reflect shifts after Trump’s election and his nominations for top HHS and FDA roles.
  • 5 FDA Decisions to Watch in Q1 2025
    5 FDA Decisions to Watch in Q1 2025 FDA Discover the top 5 FDA decisions to watch in Q1 2025, including key drug approvals like Leqembi for Alzheimer's, Dato-DXd for breast cancer, and more groundbreaking treatments.
  • FDA 2025 Q1 Approval Overview (II)
    FDA 2025 Q1 Approval Overview (II) FDA Drug Approvals Explore the FDA 2025 Q1 approval overview, featuring groundbreaking treatments like Vimseltinib for TGCT, Mirdametinib for NF1-PN, and innovative therapies in oncology, immunology, and more.
  • FDA 2025 Q1 Approval Overview (I)
    FDA 2025 Q1 Approval Overview (I) FDA Drug Approvals The FDA's 2025 Q1 approval pipeline includes promising treatments for diabetes, cancer, and central nervous system disorders. Key candidates include Ozempic for kidney disease, Subvenite for epilepsy, and TX05, a HER2-targeted cancer biosimilar.
  • FDA Approvals Summary - December 2024
    FDA Approvals Summary - December 2024 FDA Drug Approvals The FDA approved several major drugs in December 2024, including treatments for Alzheimer's, cystic fibrosis, hemophilia, and cancer. This list highlights key drugs like Zepbound, Alyftrek, and Ensacove, marking significant advances in various therapeutic areas.
< Pre 12345678...10Next >
镇原县| 乌恰县| 长沙市| 祁东县| 漳浦县| 应用必备| 平塘县| 胶州市| 万荣县| 伊宁县| 内乡县| 东光县| 平南县| 介休市| 河源市| 灯塔市| 防城港市| 南京市| 南溪县| 抚宁县| 齐河县| 碌曲县| 鄂伦春自治旗| 苏尼特右旗| 三穗县| 阿拉善右旗| 昭觉县| 四子王旗| 德庆县| 崇信县| 阳高县| 龙海市| 武冈市| 自贡市| 泾川县| 邢台县| 大洼县| 资溪县| 竹溪县| 上思县| 忻城县|